Risk of Guillain-Barré syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada
Autor(es)De Wals Philippe,Deceuninck Geneviève,Boucher Renée-Myriam,Ouakki Manale
ResumoTo assess the risk of Guillain-Barré syndrome (GBS) following administration of meningococcal serogroup C-CRM(197) conjugate vaccine, provincial immunization records were linked with hospital discharge records, and medical charts were reviewed. In the cohort of 1.9 million individuals (age, 2 months to 20 years), observed postvaccination frequencies of GBS were not higher than expected.
ImprentaClinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America: an official publication of the Infectious Diseases Society of America, v. 46, n. 8, p. e75-e77, 2008
Identificador do Objeto Digital10.1086/533469
DescritoresGuillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Vaccine ; Guillain-Barre Syndrome - Epidemiology ; Guillain-Barre Syndrome - Public health
Data de Publicação:2008
